A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact on the Progression of Type 1 diabetes

Trial Profile

A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact on the Progression of Type 1 diabetes

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DIAGNODE-2
  • Sponsors Diamyd Medical AB
  • Most Recent Events

    • 21 Sep 2017 According to a Diamyd Medical AB media release, Spanish and Czech Competent Authorities and the relevant Ethics Committees have approved Diamyd Medical's application to conduct DIAGNODE-2 trial.
    • 12 Sep 2017 New source identified and integrated (European Clinical Trials Database EudraCT2017-001861-25)
    • 27 Jun 2017 According to a Diamyd Medical AB media release, company has recieved the approval for conducting this trial from the Swedish Medical Products Agency.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top